SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DZOO who wrote (1584)6/30/1998 7:37:00 PM
From: Roudy  Read Replies (1) of 1762
 
In speaking with IDEC IR today, we spoke about the current price and what can be done about it. Their belief is the financials will speak for themselves. The quarterly reports will be out on the 14th from Genetech which will reveal Rituxan sales and IDEC will report their numbers on the 20th.

Victor Securities rating of neutral today is somewhat curious. We have several other analyst who are not in agreement with this view. But, more interesting is the same analyst gave Coulter an accumulate rating today. Coulter is trading higher than IDEC and doesn't even have a product to market. Seems to me the one first to market should be reaping the rewards, unless the product isn't selling. But so far, all indications show it is doing very well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News